SLC6A3 and Parkinson disease: Considering the AD-PD pathology interplay, and assuming that GLUT2 cell-expression is a toxicity target, it could be expected that there is a co-expression of GLUT2 and DAT, but there are no direct evidence for this in ex vivo histology analysis.